Start free trial
Trending New Genres Authors
EnglishEnglish
EspañolSpanish
简体中文Chinese
繁體中文Chinese (Traditional)
FrançaisFrench
DeutschGerman
日本語Japanese
PortuguêsPortuguese
ItalianoItalian
한국어Korean
РусскийRussian
NederlandsDutch
العربيةArabic
PolskiPolish
हिन्दीHindi
Tiếng ViệtVietnamese
SvenskaSwedish
ΕλληνικάGreek
TürkçeTurkish
ไทยThai
ČeštinaCzech
RomânăRomanian
MagyarHungarian
УкраїнськаUkrainian
IndonesiaIndonesian
DanskDanish
SuomiFinnish
БългарскиBulgarian
עבריתHebrew
NorskNorwegian
HrvatskiCroatian
CatalàCatalan
SlovenčinaSlovak
LietuviųLithuanian
SlovenščinaSlovenian
СрпскиSerbian
EestiEstonian
LatviešuLatvian
فارسیPersian
മലയാളംMalayalam
தமிழ்Tamil
اردوUrdu
Searching...
SoBrief
Ending Parkinson's Disease

Ending Parkinson's Disease

A Prescription for Action
Parkinson's cases are surging. How much of the rise could prevention and policy reverse?
by Ray Dorsey 2020 336 pages
4.31
328 ratings
Listen
Immersive
V2.3
Amazon Kindle Audible
Try Full Access for 3 Days
Unlock listening & more!
Continue

Key Takeaways

Treat Parkinson's as an industrial-age crisis, not simply an inevitable cost of aging

A rapid global rise. Parkinson's disease affects movement and many less visible functions, including sleep, mood, smell, and digestion. Its growth has outpaced what population aging alone explains. From 1990 to 2015, the number of people affected more than doubled, from 2.6 million to 6.3 million. The book cites a projection of at least 12.9 million by 2040, with a higher estimate of 17.5 million when additional trends are considered.

Industrial growth has consequences. The authors connect the rise to expanding exposure to certain pesticides, solvents, air pollution, and metals. The pattern is suggestive, not proof that every exposure causes disease. Their central claim is that a substantial share of the burden may be preventable, so Parkinson's should be treated as a public health challenge, not merely an individual misfortune.

Analysis

The industrial-age framing shifts attention from individual vulnerability to the conditions societies create and regulate. That is a useful change in scale: when a disease rises across populations, prevention cannot rest only on personal choices. At the same time, the word pandemic can convey inevitability or imply a single cause. Parkinson's has multiple pathways, and population trends can reflect changes in diagnosis as well as exposures. The strongest version of the argument is therefore not that industrialization explains every case, but that its hazards deserve systematic scrutiny when a growing disease burden coincides with them.

Look beyond tremors: Parkinson's can begin years before movement visibly changes

Damage precedes diagnosis. Parkinson's is associated with the loss of dopamine-producing nerve cells in the substantia nigra, a brain region important for movement. Symptoms often become obvious only after extensive cell loss. Years earlier, some people experience constipation, reduced sense of smell, sleep disturbances, depression, or fatigue. These signs do not by themselves diagnose Parkinson's, but they help explain why the disease can remain hidden.

Several routes may lead there. The authors describe Parkinson's as a group of related diseases involving different combinations of genes and environmental exposures. They also discuss the Braak hypothesis, which proposes that disease-related protein changes may begin in the gut or nose and spread toward the brain. This is an influential hypothesis, not settled fact. The discovery that the accidental chemical MPTP caused rapid parkinsonism in six people helped establish that certain toxins can damage dopamine-producing cells.

Analysis

A long preclinical phase changes the logic of both medicine and research. If symptoms emerge after substantial nerve-cell loss, waiting for a classic tremor may mean missing a valuable window for study or support. The early symptoms described here are also common in other conditions, however, so turning them into a home diagnostic checklist could cause unnecessary alarm. The productive middle ground is awareness without self-diagnosis: persistent, unexplained changes deserve evaluation, while researchers need reliable ways to distinguish early Parkinson's from the many conditions that can resemble it.

Reduce known toxic exposures instead of waiting for perfect proof of harm

Evidence comes in layers. Paraquat, a widely used herbicide, is linked in human studies to higher Parkinson's risk and can produce Parkinson-like effects in laboratory animals. Trichloroethylene, or TCE, is an industrial solvent associated with increased risk among exposed workers. It has contaminated soil and groundwater, and can also enter indoor air. The book notes that paraquat use in the United States doubled over the decade it discusses, despite bans in dozens of countries.

Association is not certainty. The authors argue that converging evidence from population studies, exposure patterns, and animal experiments supports a causal role for some chemicals. They invoke Bradford Hill's approach to judging whether an association is likely causal. Their policy recommendation is to ban or restrict chemicals with substantial evidence of harm, rather than demand certainty that is difficult to obtain before acting.

Analysis

This is a public health argument about the cost of waiting. Environmental harms can be difficult to prove one person at a time, especially when exposure happens years before diagnosis and people encounter several hazards. That delay can make conventional standards of proof poorly suited to prevention. The counterweight is that regulation also has consequences, including effects on workers, agriculture, and access to useful products. A sound policy response should pair restrictions with safer substitutes, transparent evidence reviews, and monitoring that tests whether exposure and disease patterns change.

Lower your risk through exercise, safer environments, and fewer head injuries

Some risks can be changed. The book describes evidence connecting traumatic brain injury with Parkinson's. One study found that a head injury involving loss of consciousness or amnesia was associated with about three times the risk; combining head trauma with paraquat exposure raised risk further. The link between particular sports and Parkinson's is less settled, though repeated head impacts carry other neurological concerns.

Movement and food matter too. A review of studies involving more than 500,000 people associated physical activity with a 21 percent lower risk. Consistent moderate-to-vigorous activity was associated with a larger reduction. A study of health professionals found fewer Parkinson's cases among people eating a Mediterranean-style diet than among those eating a Western-style diet. Caffeine was also associated with lower risk, but the authors do not advise smoking as prevention, given its major harms and uncertain benefit.

Analysis

These recommendations have an advantage that many preventive strategies lack: exercise and a balanced diet can support health even if their Parkinson's-specific effects prove smaller than hoped. That makes them sensible choices without requiring certainty about mechanism. Risk estimates from observational studies should still be interpreted cautiously, since people who exercise or eat differently may differ in other ways. Head injury prevention is especially important because the potential harms extend beyond Parkinson's. Prevention here is best understood as reducing several modifiable risks, not as a guarantee against disease.

Seek answers when unexplained symptoms persist, even without a tremor

The disease is often missed. Hans, a Dutch bookkeeper, spent years seeking explanations for depression, fatigue, dream enactment, shoulder pain, and changes in walking. A neurologist recognized the pattern as Parkinson's. In another case, a retired mechanic's long-standing slowness and withdrawal were treated as depression until a psychiatrist noticed his impaired movement. Levodopa brought striking improvement.

Diagnosis opens a door. The book reports that many people with Parkinson's remain undiagnosed, including 83 percent in one study in the Italian Alps and nearly half in Beijing. After diagnosis, specialist care also matters: among Medicare beneficiaries recently diagnosed, those who had not seen a neurologist were more likely to experience hip fracture, nursing-facility placement, and premature death. These findings do not mean every symptom signals Parkinson's. They do support seeking another opinion when a persistent change remains unexplained.

Analysis

The stories show how diagnostic error can come from a mismatch between a disease's popular image and its actual range of symptoms. A clinician looking only for a visible tremor may miss changes in gait, sleep, mood, or facial movement. The remedy is not to turn patients into their own neurologists, but to take their observations seriously and connect persistent patterns to appropriate expertise. Access matters here: a correct diagnosis is only useful if it leads to informed treatment, practical support, and a clinician who can reassess the picture as symptoms change.

Bring Parkinson's expertise into homes and communities, not only specialist clinics

Care needs a team. Parkinson's can affect movement, swallowing, sleep, mood, thinking, and independence, so one medication or one doctor rarely addresses every need. The Dutch ParkinsonNet model trains local professionals across disciplines and helps patients find practitioners experienced in Parkinson's. The book reports that the network reduced hip fractures by 50 percent and lowered hospital admissions.

Access can be redesigned. Telemedicine helped a nursing-home resident, John Harlan, recover after a specialist reviewed his medications remotely, removed two drugs, and arranged physical therapy. Home visits, video appointments, and Project ECHO, which connects local clinicians with remote experts for training and case consultation, offer other ways to extend care. These approaches can ease travel and caregiver burdens. Their effectiveness depends on reimbursement, local clinical capacity, and ensuring that people without reliable technology are not left behind.

Analysis

The care models described here treat expertise as something that can be distributed rather than confined to major medical centers. That is a systems insight: better outcomes can come from training, coordination, and continuity, not only from discovering a new drug. Remote care also changes what counts as a useful clinical visit by making it possible to observe patients in daily settings. Still, technology is a bridge, not a substitute for human care. Patients need in-person assessment when appropriate, and the caregiver's knowledge should inform care without silently making the caregiver responsible for the entire system.

Turn the Parkinson's community's experience into organized public pressure

Other movements changed the terms. The March of Dimes mobilized public giving and helped finance polio care and vaccine research. AIDS activists confronted stigma, built community support, challenged drug prices, and pressed regulators to include patients in research decisions. Breast cancer advocates and public figures made a once-hidden illness harder to ignore. These movements used different tactics, but each connected lived experience to public attention, funding, and policy.

The book's PACT. Its proposed framework means Preventing disease, Advocating for policy and resources, Caring for everyone affected, and Treating Parkinson's with better therapies. Patients, caregivers, clinicians, families, and allies all have a role. The authors argue that this community can press for restrictions on hazardous chemicals, better care, stronger research, and fair access to treatment. The lesson is not that every tactic from another movement should be copied, but that silence and fragmentation make it easier for institutions to delay.

Analysis

The comparison with AIDS activism is especially instructive because it makes patient participation part of scientific governance, not merely fundraising or public relations. People living with disease can identify burdens that researchers and regulators may overlook, and their presence can make institutions more answerable to those affected. Yet activism must preserve trust as well as generate pressure. Dramatic messaging can mobilize support, but it can also flatten uncertainty or overpromise. A durable movement pairs urgency with scientific honesty and broad coalitions that include those exposed to risk, not only those already diagnosed.

Invest in prevention and objective measures, not only incremental symptom relief

Research needs better tools. Levodopa remains highly effective for many symptoms, but it does not stop the underlying disease and can cause complications with long-term use. The authors describe experimental approaches including therapies aimed at LRRK2 or GBA gene pathways, antibodies against misfolded alpha-synuclein, and adaptive deep brain stimulation. These approaches are promising, not proven cures.

Measurement is a bottleneck. Parkinson's severity is still often judged by clinician observation and rating scales that can miss small changes. Smartphone voice and movement tests, wearable sensors, and large remote studies could measure symptoms more often and in everyday life. The book notes that inflation-adjusted NIH funding for Parkinson's research fell 8 percent from 2008 to 2018 even as estimated US cases rose. Better funding and shared data could improve prevention research, clinical trials, and treatment development.

Analysis

The emphasis on measurement is more than a technical detail. If a disease fluctuates and available scales are blunt, a useful treatment can look ineffective, while a weak result can be hard to interpret. Digital tools could make research more continuous and inclusive, particularly for people far from academic centers. But more data do not automatically mean better knowledge. Sensors can misclassify ordinary variation, and participants who use smartphones may not represent everyone affected. Measurement systems need validation, privacy safeguards, and patient input alongside the ambition to scale research.

Make effective Parkinson's care affordable and available wherever patients live

Access is part of treatment. Levodopa is inexpensive in many wealthy countries, yet the book cites a World Health Organization report finding that 40 percent of countries lacked access to it. Access was especially limited in low-income countries. Advanced procedures such as deep brain stimulation are also concentrated in major medical centers, while many patients struggle to reach specialists or rehabilitation.

Payment shapes care. In the United States, Medicare pays far more for complications such as a broken hip and institutional care than for preventive visits or community services. The result is a system that can reward crisis management while neglecting support that helps people stay at home. The authors call for coverage of telemedicine and home care, patient representation in payment decisions, reasonable drug prices, and research participation that does not require repeated travel.

Analysis

The book's equity argument exposes a distinction between treatment existing and treatment being usable. A medicine on a shelf, a specialist hours away, or a virtual visit that insurance will not cover does not amount to meaningful access. This is a familiar problem in health systems: payment rules shape clinical behavior, often without explicitly deciding what patients need. Reform therefore has to address logistics and financing as well as innovation. Equal access will also require attention to groups the book identifies as underserved, including women, older adults, and African Americans.

Analysis

The book's strongest contribution is its insistence that Parkinson's is not only a clinical problem but also an environmental and institutional one. It links the histories of industrial chemicals, pesticide use, and pollution to a disease whose symptoms may appear long after exposure. That time lag makes responsibility difficult to assign and prevention easy to postpone. The authors respond by combining individual risk reduction with regulation, better surveillance, accessible care, and organized advocacy. The resulting argument is more useful than a simple lifestyle prescription because it identifies both personal and structural levers.

The evidence is persuasive in its convergence, but its certainty varies. Human studies often identify associations rather than direct causation, exposure histories are difficult to reconstruct, and Parkinson's itself is biologically heterogeneous. Animal models show that chemicals can damage relevant nerve cells, but they cannot establish the exact risk faced by a person in a particular setting. The book sometimes moves quickly from this layered evidence to a confident policy conclusion. A careful reading should retain the distinction between a plausible hazard, a measured population association, and a proven cause in an individual case.

That distinction does not require passivity. Public health decisions routinely occur before every mechanism and individual risk is known, especially when exposure is widespread and alternatives exist. The more demanding standard should be transparent assessment: measure exposure, disclose uncertainty, monitor outcomes, and revise policy as evidence improves. The book's demand for better disease registries and objective measurements supports exactly that approach.

Its advocacy framework also recognizes that scientific progress depends on social organization. Patients are not merely recipients of care or subjects in trials. Their participation can shape priorities, improve research design, and expose failures of access. The most durable version of the book's call to action combines urgency with restraint: prevent avoidable exposure, improve care now, and pursue therapies without promising that one discovery will end every form of Parkinson's. The goal is not to blame individuals or declare the disease fully understood. It is to stop treating preventable suffering as inevitable.

Summary in 30 Seconds
Parkinson's cases more than doubled worldwide between 1990 and 2015, reaching 6.3 million; projections suggest at least 12.9 million by 2040. Some pesticide and solvent exposures are linked to higher risk, though evidence does not establish every exposure as a cause. Exercise is associated with lower risk, while early symptoms can precede movement changes. Specialist teams, remote care, and broader access can reduce complications. Prevention, research, and patient advocacy all need stronger public support.
Contains spoilers

Last updated:

Report Issue

Review Summary

4.31 out of 5
Average of 328 ratings from Goodreads and Amazon.

Ending Parkinson's Disease receives mostly positive reviews, with readers praising its informative content, accessibility, and call to action. Many appreciate the authors' expertise and the book's comprehensive coverage of Parkinson's history, causes, and potential solutions. Some readers found hope in the book's message, while others felt it focused too heavily on environmental factors and advocacy. A few criticisms mention the book's US-centric approach and limited practical advice for individuals with Parkinson's. Overall, readers recommend it for those seeking to understand the disease and its broader implications.

Your rating:
4.6
126 ratings
Want to read the full book?

Glossary

PACT

Four-part action framework

The book's organizing framework for responding to Parkinson's disease: Prevent the disease, Advocate for policies and resources, Care for everyone affected, and Treat the condition with better therapies. It connects environmental prevention and political action with present-day clinical support and research, emphasizing that no single intervention can address the full burden.

Parkinsonism

Parkinson-like movement syndrome

A general term for a group of symptoms that can include tremor, slowed movement, stiffness, and problems with balance. Parkinson's disease is the most common cause, but medications, toxins, infections, and other neurological diseases can also produce parkinsonism. The distinction matters because similar outward symptoms may have different causes and require different treatment.

MPTP

Dopamine-neuron-damaging chemical

A toxic chemical accidentally produced while people were synthesizing a street drug related to an opioid. In the brain, MPTP is converted into MPP+, which damages dopamine-producing nerve cells in the substantia nigra. Exposure caused rapid, severe parkinsonism in several people and gave researchers a way to study toxin-related damage in animals.

Lewy bodies

Clumps of misfolded proteins

Abnormal clusters found inside nerve cells in the brains of most people with Parkinson's disease. They contain misfolded alpha-synuclein and other proteins. Their presence is a characteristic marker of Parkinson's-related pathology, although the precise role they play in the disease process remains under investigation.

ParkinsonNet

Network of trained care professionals

A Dutch model of Parkinson's care that trains professionals from multiple disciplines and connects patients to clinicians with substantial experience treating the disease. It also supports patient knowledge and cooperation among providers. The book describes its expansion beyond the Netherlands and reports improved outcomes, including fewer hip fractures and hospital admissions.

Braak hypothesis

Possible gut-to-brain disease route

A proposal that Parkinson's-related pathology may begin outside the brain, potentially in nerves involved in smell or digestion, and then spread toward brain regions that control movement and thinking. The hypothesis is supported by observations of disease-related protein changes in some non-brain tissues, but it remains a proposed account rather than a settled explanation for every case.

Deep brain stimulation

Adjustable electrical brain stimulation

A surgical treatment in which electrodes are placed in targeted brain regions and connected to a battery-powered device under the skin. Electrical stimulation can reduce certain movement symptoms and medication-related involuntary movements in selected patients. Settings can be adjusted as symptoms change, but the procedure does not cure Parkinson's or halt its progression.

About the Author

Ray Dorsey is a prominent neurologist and researcher specializing in Parkinson's disease. He is the David M. Levy Professor of Neurology and Director of the Center for Health + Technology at the University of Rochester Medical Center. Dorsey has authored numerous scientific publications and is known for his work on telemedicine and digital health in neurology. He is a passionate advocate for improving care and finding a cure for Parkinson's disease. Dorsey's expertise in movement disorders and his commitment to patient-centered care have made him a leading voice in the field. His collaborative approach to research and advocacy is evident in his co-authorship of "Ending Parkinson's Disease" with other experts in the field.

Download PDF

To save this Ending Parkinson's Disease summary for later, download the free PDF. You can print it out, or read offline at your convenience.
Download PDF
File size: 0.34 MB     Pages: 15

Download EPUB

To read this Ending Parkinson's Disease summary on your e-reader device or app, download the free EPUB. The .epub digital book format is ideal for reading ebooks on phones, tablets, and e-readers.
Download EPUB
File size: 1.44 MB     Pages: 20
Want to read the full book?
Follow
Listen
Home
Swipe
Library
Get App
Try Full Access for 3 Days
Listen, bookmark, and more
Compare Features Free Pro
📖 Read Summaries
Read unlimited summaries. Free users get 3 per month
🎧 Listen to Summaries
Listen to unlimited summaries in 40 languages
—
❤️ Unlimited Bookmarks
Free users are limited to 4
—
📜 Unlimited History
Free users are limited to 4
—
📥 Unlimited Downloads
Free users are limited to 1
—
Risk-Free Timeline
Today: Get Instant Access
Listen to full summaries of 26,000+ books. That's 12,000+ hours of audio!
Day 2: Trial Reminder
We'll send you a notification that your trial is ending soon.
Day 3: Your subscription begins
You'll be charged on Nov 25,
cancel anytime before.
Consume 2.8× More Books
2.8× more books Listening Reading
Our users love us
1M+ readers
Trustpilot Rating
TrustPilot
4.6 Excellent
This site is a total game-changer. I've been flying through book summaries like never before. Highly, highly recommend.
— Dave G
Worth my money and time, and really well made. I've never seen this quality of summaries on other websites. Very helpful!
— Em
Highly recommended!! Fantastic service. Perfect for those that want a little more than a teaser but not all the intricate details of a full audio book.
— Greg M
Save 62%
Yearly
$119.88 $44.99/year/yr
$3.75/mo
Monthly
$9.99/mo
Start a 3-Day Free Trial
3 days free, then $44.99/year. Cancel anytime.
Unlock a world of fiction & nonfiction books
26,000+ books for the price of 2 books
Read any book in 10 minutes
Discover new books like Tinder
Request any book if it's not summarized
Read more books than anyone you know
#1 app for book lovers
Lifelike & immersive summaries
30-day money-back guarantee
Download summaries in EPUBs or PDFs
Cancel anytime in a few clicks

Why one summary?

Scanner
Find a barcode to scan

⭐
⭐
⭐
We have a special gift for you
Open
38% off
DISCOUNT FOR YOU
⭐
⭐
⭐
$79.99
$49.99/year
Only $4.16 per month
Continue
2 taps to start, super easy to cancel
Settings
General
Widget
Loading...